X-linked complex spastic paraplegia Advocacy Hub | UniteRare

At a Glance

Live from database

💰

1Open funds

📰

3Recent news

Regulatory Watchboard

10 events

Mar 2026

CABERGOLINE: New indication approved

FDAcompleted

Mar 2026IOPIDINE 1%: New indication approved

FDAcompleted

Mar 2026

OXALIPLATIN: New indication approved

FDAcompleted

Mar 2026TOBRADEX ST: New indication approved

FDAcompleted

Feb 2026REBLOZYL: New indication approved

FDAcompleted

Jan 2026ALVAIZ: New indication approved

FDAcompleted

Feb 2022

OXALIPLATIN: New indication approved

FDAcompleted

Dec 2019

CABERGOLINE: New indication approved

FDAcompleted

Mar 2017

OXALIPLATIN: FDA approved

FDAcompleted

Oct 2011

CABERGOLINE: New indication approved

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance1

MIPLYFFA

Acer Therapeutics Inc.

OpenContact for details

View all support programs on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for X-linked complex spastic paraplegia.
Search all trials →

Search clinical trials for X-linked complex spastic paraplegia →

Recent News & Research

3 articles

BREAKINGFDA

FDA Approves CABERGOLINE

CABERGOLINE (CABERGOLINE) received FDA approval.

Read ↗

BREAKINGFDA

FDA Approves OXALIPLATIN

OXALIPLATIN (OXALIPLATIN) received FDA approval.

Read ↗

BREAKINGFDA

FDA Approves TOBRADEX ST

TOBRADEX ST (DEXAMETHASONE) received FDA approval.

Read ↗

Browse all X-linked complex spastic paraplegia news →

Specialist Network

No specialists currently listed for X-linked complex spastic paraplegia.

View all X-linked complex spastic paraplegia specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰